相关临床试验
32
26 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
26
81.3%
已完成
3
9.4%
招募中
3
9.4%
- The ROSELLA trial is evaluating relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. - Early-phase studies suggest relacorilant can reverse cortisol's antiapoptotic effects, potentially enhancing chemotherapy efficacy in tumors overexpressing glucocorticoid receptors. - Phase 2 data showed intermittent relacorilant plus nab-paclitaxel improved progression-free survival and duration of response compared to nab-paclitaxel alone. - The ROSELLA trial has completed enrollment and aims to confirm these findings in a larger patient population across North America and Europe.
- Corcept Therapeutics has completed enrollment in the Phase III ROSELLA study evaluating relacorilant plus Abraxane for recurrent, platinum-resistant ovarian cancer. - The primary endpoint of the ROSELLA study is progression-free survival, with overall survival as a key secondary endpoint; data is expected by late 2024. - Relacorilant is also being evaluated in Phase III trials for Cushing's syndrome and in combination with Keytruda for adrenal cancer, with data readouts expected in 2024.
